Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Pipeline Review, H2 2019
Summary
According to the recently published report 'Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Pipeline Review, H2 2019'; Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 Inhibitor of nuclear factor kappaB kinase subunit beta is a protein encoded by the IKBKB gene. It plays an essential role in the NFkappaB signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. It acts as part of the canonical IKK complex in the conventional pathway of NFkappaB activation and phosphorylates inhibitors of NFkappaB on 2 critical serine residues. Free NFkappaB is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis.
The report 'Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Pipeline Review, H2 2019' outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Gastrointestinal which include indications Inflammation, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Breast Cancer, Colorectal Cancer, Glioblastoma Multiforme GBM, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer and Solid Tumor.
Scope
The report provides a snapshot of the global therapeutic landscape for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10
The report reviews Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 targeted therapeutics and enlists all their major and minor projects
The report assesses Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope